Blood tumor mutational burden and dynamic changes in circulating tumor DNA predict response to pembrolizumab treatment in advanced non-small cell lung cancer

por Stensgaard, Simone, Thomsen, Astrid, Helstrup, Sofie, Meldgaard, Peter, Sorensen, Boe S.
Publicado 2023

Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials

por Eide, Inger Johanne Zwicky, Stensgaard, Simone, Helland, Åslaug, Ekman, Simon, Mellemgaard, Anders, Hansen, Karin Holmskov, Cicenas, Saulius, Koivunen, Jussi, Grønberg, Bjørn Henning, Sørensen, Boe Sandahl, Brustugun, Odd Terje
Publicado 2022